List: $34B In Pharma Sales Lose Patent in 2014
The very smart and hard-working Tracy Staton at FiercePharma puts together some of the most useful lists for investors in the healthcare field, and few deserve as close a reading as her recent list of the top drugs facing patent expiration in 2014.
The total amount of industry sales facing patent expiration next year is $34 billion, Staton reports. That’s up from $28 billion during 2013. Bigger expiration years? $55 billion in 2012. And watch out for 2015: $66 billion.
Equity research tools can help better understand each company's situation. Here is the top five for 2014, with charts to provide context on the affected companies, according to Staton and FiercePharma:
Teva’s (TEVA) Copaxone, with global 2012 sales of $4 billion, loses protection in May 2014. It’s a multiple sclerosis treatment.
AstraZeneca’s (AZN) Nexium, global sales of about $4 billion, loses patent protection in May 2014. Nexium treats heartburn and reflux.
Boehringer Ingelheim’s Micardis, global sales of about $2.2 billion, goes off patent in January 2014. Micardis treats hypertension. Boehringer is privately-held.
Novartis (NVS) is losing patent protection on two big drugs. Its Sandostatin LAR, global sales $1.5 billion, goes off patent in June 2014. It treats cancer. And its Exforge, global sales about $1.4 billion, goes off patent in October 2014.
(These patent expiration dates are generally U.S. dates. Expirations in other countries occur at different dates, frequently. And the percentage of global sales that occur in the U.S. among these drugs varies widely, as you can see by reading the full FiercePharma report.)
Jeff Bailey, The Editor of YCharts, is a former reporter, editor and columnist at the Wall Street Journal and New York Times. He can be reached at firstname.lastname@example.org. Read the RIABiz profile of YCharts. You can also request a demonstration of YCharts Platinum.